Definitive Healthcare Corp (DH)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $140.38M
Last updated: Nov 17, 2026 at 11:02 AM ET
Definitive Healthcare Corp (DH) P/E Ratio & Valuation History
Definitive Healthcare (DH) trades at 9.0x trailing earnings and 0.6x sales. Its P/E of 9.0x is below its 5-year median of 16.6x. Its forward P/E is 6.9x. The median P/E across 5 similar companies is 13.2x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 30.4% higher over the next year. Its free cash flow yield is 18.0%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 9.0x |
| Forward P/E | 6.9x |
| Price to sales | 0.6x |
| Price to book | 0.9x |
| Price to FCF | 5.6x |
| EV/FCF | 4.8x |
| PEG | N/A |
| FCF yield | 18.0% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 9.0x | 16.6x | N/A |
| P/S | 0.6x | 2.5x | N/A |
| P/B | 0.9x | 1.1x | N/A |
Valuation History
Over the 4 of the 5 year ends shown that have a P/E, its P/E ranged from 11.7x in 2024 to 45.8x in 2022.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $2.87 | 14.3x | 1.3x | 1.1x |
| 2024 | $4.11 | 11.7x | 1.9x | 1.1x |
| 2023 | $9.94 | 33.1x | 4.5x | 1.3x |
| 2022 | $10.99 | 45.8x | 5.0x | 1.2x |
| 2021 | $27.33 | N/A | 14.7x | 2.9x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DH
What is DH's forward P/E ratio?
Definitive Healthcare has a forward P/E ratio of 6.9x.
Is DH stock overvalued?
GNG's valuation label for DH is Undervalued. Its P/E of 9.0x compares with a median of 13.2x across 5 similar companies.
What is DH's price to sales ratio?
Definitive Healthcare has a price to sales ratio of 0.6x.
What is Definitive Healthcare's average P/E ratio over 5 years?
Definitive Healthcare's median P/E over the last 5 years is 16.6x, from 56 month-end values through Oct 2026.
DH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts